Capecitabine, DNA/RNA Synthesis Inhibitor

Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. - Mechanism of Action & Protocol.

Emerging strategies for cancer therapy by ATR inhibitors - Yano - 2023 - Cancer Science - Wiley Online Library

Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer - Clifford - 2018 - BJS (British Journal of Surgery) - Wiley Online Library

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy, Journal of Hematology & Oncology

Frontiers PARP inhibitors combined with radiotherapy: are we ready?

Metabolic conversion of capecitabine to 5-fluorouracil

Effects of microbiota on anticancer drugs: Current knowledge and potential applications - eBioMedicine

Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil

Capecitabine, DNA, RNA and Protein Synthesis Inhibitors

POR Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer